Gerresheimer AG (ETR:GXI – Get Free Report) fell 0.3% during mid-day trading on Thursday . The stock traded as low as €58.85 ($66.12) and last traded at €59.20 ($66.52). 97,465 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 140,925 shares. The stock had previously closed at €59.35 ($66.69).
Gerresheimer Stock Performance
The company has a debt-to-equity ratio of 87.94, a current ratio of 0.80 and a quick ratio of 0.40. The company’s fifty day moving average price is €65.24 and its 200 day moving average price is €71.07. The company has a market cap of $2.07 billion, a PE ratio of 18.12, a P/E/G ratio of 0.82 and a beta of 0.94.
Gerresheimer Company Profile
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.
See Also
- Five stocks we like better than Gerresheimer
- How to Invest in Biotech Stocks
- IBM’s AI Offensive: Assessing IBM’s Path to Renewed Growth
- Why is the Ex-Dividend Date Significant to Investors?
- Rockwell Automation: Tailwinds From Onshoring U.S. Production
- Consumer Discretionary Stocks Explained
- Is Energy Transfer Undervalued or a Value Trap?
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.